Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL pos TYRO3 over exp |
| Therapy | Dubermatinib |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL pos TYRO3 over exp | chronic lymphocytic leukemia | sensitive | Dubermatinib | Preclinical | Actionable | In a preclinical study, Dubermatinib (TP-0903) inhibited survival and induced apoptosis in Axl-positive and Tyro3-over expressing B-cells derived from chronic lymphocytic leukemia patients (PMID: 25673699). | 25673699 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25673699) | Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. | Full reference... |